Brenda Libby Coleman

Array ( [id] => 15163225 [patent_doc_number] => 10487092 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors [patent_app_type] => utility [patent_app_number] => 15/537694 [patent_app_country] => US [patent_app_date] => 2015-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 40402 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15537694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702435 [patent_doc_number] => 20170362172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 15/534546 [patent_app_country] => US [patent_app_date] => 2015-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15534546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551223 [patent_doc_number] => 10344053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Inhibitors for inhibiting tumor metastasis [patent_app_type] => utility [patent_app_number] => 15/535002 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8154 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15535002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714125 [patent_doc_number] => 20170368017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => ANTIBACTERIAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 15/534874 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15534874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058579 [patent_doc_number] => 20170334924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors' [patent_app_type] => utility [patent_app_number] => 15/533169 [patent_app_country] => US [patent_app_date] => 2015-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30200 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14948295 [patent_doc_number] => 10435406 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => 6,7-cyclicmorphinan derivatives and use thereof [patent_app_type] => utility [patent_app_number] => 15/533266 [patent_app_country] => US [patent_app_date] => 2015-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22631 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 441 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14977837 [patent_doc_number] => 10442819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Tricyclic compounds as inhibitors of mutant IDH enzymes [patent_app_type] => utility [patent_app_number] => 15/532549 [patent_app_country] => US [patent_app_date] => 2015-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58613 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 870 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15532549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051149 [patent_doc_number] => 20170327493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'CXCR7 RECEPTOR MODULATORS' [patent_app_type] => utility [patent_app_number] => 15/526983 [patent_app_country] => US [patent_app_date] => 2015-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52321 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15526983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12509145 [patent_doc_number] => 10000499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => Methyl diazepane orexin receptor antagonists [patent_app_type] => utility [patent_app_number] => 15/529764 [patent_app_country] => US [patent_app_date] => 2015-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14046 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15529764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051435 [patent_doc_number] => 10047098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use [patent_app_type] => utility [patent_app_number] => 15/527975 [patent_app_country] => US [patent_app_date] => 2015-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35305 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 748 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15527975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030777 [patent_doc_number] => 20170320876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/529769 [patent_app_country] => US [patent_app_date] => 2015-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21488 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15529769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030809 [patent_doc_number] => 20170320907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => '5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS' [patent_app_type] => utility [patent_app_number] => 15/528220 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16524 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15528220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689501 [patent_doc_number] => 20170355705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS [patent_app_type] => utility [patent_app_number] => 15/527440 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 152408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15527440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11596778 [patent_doc_number] => 09643929 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-09 [patent_title] => 'Asymmetric catalytic reduction of oxcarbazepine' [patent_app_type] => utility [patent_app_number] => 14/944546 [patent_app_country] => US [patent_app_date] => 2015-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7598 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14944546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915335 [patent_doc_number] => 09783512 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Bicyclic methylene aziridines and reactions thereof' [patent_app_type] => utility [patent_app_number] => 14/940586 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 39538 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12408504 [patent_doc_number] => 09969767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Oxolupene derivatives [patent_app_type] => utility [patent_app_number] => 15/524298 [patent_app_country] => US [patent_app_date] => 2015-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20692 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 789 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12975604 [patent_doc_number] => 20170340618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => 2-Amino-5,5-Difluoro-6-(Fluoromethyl)-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors [patent_app_type] => utility [patent_app_number] => 15/524565 [patent_app_country] => US [patent_app_date] => 2015-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058572 [patent_doc_number] => 20170334916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/523769 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40651 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 36 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15523769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784125 [patent_doc_number] => 20160130282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/934510 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15063 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14934510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12057092 [patent_doc_number] => 20170333435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/523774 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41097 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 30 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15523774 [rel_patent_id] =>[rel_patent_doc_number] =>)